**Author details**

**3. Meniett device**

170 Up to Date on Meniere's Disease

pressure in the middle ear.

**4. Vestibular rehabilitation**

stabilized vestibular function [44].

consequences that have been promoted.

**5. Conclusion**

H2

During the decade of 1970, the demand for a more effective and a nondestructive method for the treatment of MD, Inglestad et al. [41] observed that some patients reported improvement with changes of pressure in a pressure chamber. Densert et al. [42] showed that the manipulation of the middle ear pressure influences the pressure in the inner ear; later, improved hearing and dizziness in patients with MD were described after the application of positive

Additionally, there was improvement of the cochlear electrical potentials after administration of positive pressure in the middle ear, which finally led to the development of the device

The Meniett device emits a pulse of repeated pressure of 0.6 second in the range of 0–20 cm

The FDA approved the use of the device in 2002, demand is still low, despite recent work showing the effectiveness of the device. Meniett reduces the frequency of dizziness in patients with Meniere's disease activity, an improvement of AAO-HNS Meniere's disease functional level scale, but the device does not significantly improve hearing, showing a safe option for

Vestibular rehabilitation is a form of body and eye movement stimulation therapy designed to improve vestibular function and mechanisms of central adaptation and compensation. It is mainly useful to treat the MD squeal; vestibular adaptation exercises to prevent falls have proven to be particularly effective. This type of treatment is quite effective for patients with

Treatments in Meniere's disease are generally aimed at reducing the acute symptomology vertiginous episodes. The cure currently does not exist. To date, the treatment has convincingly been shown to be effective in altering the natural course of the disease, thereby preventing end organ damage, which results in hearing loss and vestibular impairment. The clinical spectrum of the disease of Meniere's symptoms is wide, with the possibility of remission and recurrence of symptoms, and even fairly unfavorable developments, with irreversible hearing loss and damage the vestibular function. A good treatment must be individualized for each patient, taking into consideration these possibilities, the stage of disease, and the possible

O at 6 Hz. Treatment consists of three to four cycles of a sequence of treatment of 5 min, this device requires only a short-term ventilation tube (Sheppard) to allow the transmission

known as the Meniett (Medtronic Xomed Surgical Products, Jacksonville, FL).

of impulses in an auditory external pressure to the middle ear.

patients with refractory diseases to the conventional treatments [43].

Eduardo Amaro Bogaz1,2\*, André Freitas Cavallini da Silva<sup>1</sup> , Davi Knoll Ribeiro1 and Gabriel dos Santos Freitas<sup>1</sup>


2 Department of Otology and Neurotology, São Camilo Hospital, São Paulo, Brazil

## **References**


[25] Burneo JG, Montori VM, Faught E. Magnitude of the placebo effect in randomized trials of antiepileptic agents. Epilepsy & Behavior. 2002;**3**(6):532-534

[11] Burgess A, Kundu S. Diuretics for Ménière's disease or syndrome. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD003599. DOI: 10.1002/14651858.CD003599.

[12] Lacour M, Sterkers O. Histamine and betahistine in the treatment of vertigo: Elucidation

[13] Van Cauwenberge PB, De Moor SE. Physiopathology of H3-receptors and pharmacol-

[14] Mira E, Guidetti G, Ghilardi L, Fattori B, Malannino N, Maiolino L, et al. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. European Archives of

[15] Lezius F, Adrion C, Mansmann U, Jahn K, Strupp M. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Meniere's disease: A case

[16] Adrion C, et al. Efficacy and safety of betahistine treatment in patients with Meniere's disease: Primary results of a long term, multicentre, double blind, randomised, placebo

[17] James A, Burton MJ. Betahistine for Ménière's disease or syndrome. Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD001873. DOI: 10.1002/14651858.CD00

[18] Ganança MM, Munhoz MSL, Caovilla HH, Silva MLG. Managing vertigo. Hannover: Solvay; 2006/Clostre F. Ginkgo biloba extract (egb761): State of knowledge in the dawn

of the year 2000. Annales Pharmaceutiques Francaises. 1999;**57**(Suppl 1):1S8-188.

[19] Ganança MM, Munhoz MSL, Caovilla HH, Silva, MLG. Managing vertigo. Hannover: Solvay; 2006/Cesarani A, Meloni F, Alpini D, Barozzi S, Verderio L, Boscani PF. Ginkgo biloba (egb 761) in the treatment of equilibrium disorders. Advances in Therapy. 1998;**15**(5):291-304 [20] Chi FL, Yang MQ, Zhou YD, Wang B. Therapeutic efficacy of topical application of dexamethasone to the round window niche after acoustic trauma caused by intensive impulse noise in guinea pigs. Journal of Laryngology and Otology. 2011;**125**(7):673-685

[21] She W, Lv L, Du X, Li H, Dai Y, Lu L, Ma X, Chen F. Long-term effects of intratympanic methylprednisolone perfusion treatment on intractable Ménière's disease. The Journal

[22] Boleas-Aguirre MS, Lin FR, Della Santina CC, Minor LB, Carey JP. Longitudinal results with intratympanic dexamethasone in the treatment of Ménière's disease. Otology &

[23] Phillips JS, Westerberg B. Intratympanic steroids for Ménière's disease or syndrome.

[24] Schuknecht HF. Ablation therapy for the relief of Meniere's disease. Laryngoscope.

controlled, dose defining trial (BEMED trial). British Medical Journal. 2016;**352**

ogy of betahistine. Acta Oto-laryngologica Supplementum. 1997;**526**:43-46

series. European Archives of Oto-rhino-laryngology. 2011;**268**:1237-1240

of mechanisms of action. CNS Drugs. 2001;**15**:853-870

Oto-Rhino-Laryngology. 2003;**260**(2):73-77

of Laryngology & Otology. 2015;**129**:232-237

Cochrane Database of Systematic Reviews. 2011;**6**(7)

Neurotology. 2008;**29**(1):33-38

1956;**66**:859-870

pub2. 1-14

172 Up to Date on Meniere's Disease

1873. 1-11

